Three percent of patients with pancreatic ductal adenocarcinoma (PDAC) present a germline pathogenic variant (GPV) associated with an increased risk of this tumor, CDKN2A being one of the genes associated with the highest risk. There is no clear consensus on the recommendations for surveillance in CDKN2A GPV carriers, although the latest guidelines from the International Cancer of the Pancreas Screening Consortium recommend annual endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) regardless of family history. Our aim is to describe the findings of the PDAC surveillance program in a cohort of healthy CDKN2A GPV heterozygotes. This is an observational analysis of prospectively collected data from all CDKN2A carriers who underwent screening for PDAC at the high-risk digestive cancer clinic of the “Hospital Clínic de Barcelona” between 2013 and 2021. A total of 78 subjects were included. EUS or MRI was performed annually with a median follow-up of 66 months. Up to 17 pancreatic findings were described in 16 (20.5%) individuals under surveillance, although most of them were benign. No significant precursor lesions were identified, but an early PDAC was detected and treated. While better preventive strategies are developed, we believe that annual surveillance with EUS and/or MRI in CDKN2A GPV heterozygotes may be beneficial.
7 July 2025 in Clinical and Translational Gastroenterology
INTRODUCTION: Accurate diagnosis of mucinous pancreatic cystic neoplasms (mPCNs) remains a clinical challenge. This study investigated the utility of single GNAS droplet-based digital polymerase chain reaction (ddPCR) analysis as a novel approach to refine the diagnostic accuracy of mPCNs using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). METHODS: Patients who underwent EUS-FNA and GNAS pancreatic cyst fluid (PCF) analyses for pancreatic cystic lesion (PCL) assessment were prospectively enrolled. Cysts were categorized as mPCNs, non-mPCNs, or inconclusive PCLs (iPCLs) by integrating increasing information levels: high-resolution imaging and non-DNA PCF features (level 1), GNAS PCF analysis (level 2), and surgical pathology (level 3). RESULTS: One hundred forty patients were included, 25 of whom underwent pancreatic surgery. Level 1 identified 68 mPCNs (49%), 24 non-mPCNs (17%), and 48 iPCLs (34%). GNAS mutations were detected in 42 of 68 (62%) mPCNs, 1 of 24 (4%) non-mPCNs, and 16 of 48 (33%) iPCLs. Level 2 increased mPCN detection to 62% and reduced iPCLs by one-third. Mutated GNAS showed 66% sensitivity for diagnosing mPCNs in the whole cohort and 65% in resected cases, outperforming both imaging and non-DNA PCF mucinous criteria, with 100% specificity and limited concordance with carcinoembryonic antigen, cytology, and fluid viscosity, highlighting its complementary diagnostic value. Cost-effectiveness simulations for iPCLs demonstrated that GNAS-ddPCR significantly reduced diagnostic costs by 24% compared with next-generation sequencing testing. DISCUSSION: Single GNAS-ddPCR analysis in PCF supported mPCNs diagnosis in 62% of cases and uncovered 33% of iPCLs as mPCNs with 100% specificity. It adds complementary value to standard cyst fluid markers offering a simple and cost-effective tool for improving PCL diagnosis by EUS-FNA.
Fluorescence Confocal laser microscopy (FCM) with Vivascope in EUS-fine needle biopsy (FNB) samples of pancreatic solid lesion has shown good concordance with final histological evaluation.To assess the accuracy of Vivascope in predicting the diagnosis of EUS-guided pancreatic solid lesions samples.To assess the agreement between Vivascope and final histological diagnosis and the possible association between type and size of needles and the histological diagnosis obtainment. Multicentre prospective study involving 3 European referral Endoscopy Units. Consecutive patients undergoing EUS-guided sampling of pancreatic solid masses were enrolled. The same samples were assessed by Vivascope and conventional pathology and classified as "Inadequate" or "Adequate" (Benign; Suspicious; Malignant). From April to August 2023 80 patients enrolled. In 78.5% FNB needle was used and in 66.3% it was a 22G needle.The FCM diagnosis with Vivascope was confirmed in 94.8% patients after conventional pathology.The use of FNB needle was not associated with higher rate of diagnostic samples at Vivascope evaluation (88.8% vs 100%, p=0.33), neither were the needle size (19 G 100% vs 22 G 88.7% vs 25 G 96.2 p=0.52) or the sampling technique (93.9% vs 78.5% p=0.09). Vivascope sensitivity was 97.33% (95% CI 90.7-99.7%), Specificity was 80.0% (95% CI 28.4-99.5%) and Accuracy 96.3% (95% CI 89-99.2%).There was moderate concordance between FCM diagnosis with Vivascope and the final histological diagnosis (kappa Cohen's coefficient 0.58). Our study supports the reliability of FCM with Vivascope for both sample adequacy and diagnosis.It may prevent possible diagnostic delays and allowing centralization of microscopic assessment thanks to its digital nature.